Highlights: ● The study compared IHL-216A to its component drugs, cannabidiol (CBD) and isoflurane, in a model developed in collaboration… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical… Read more
A pro-rata non-renounceable offer to Eligible Shareholders of one Loyalty Option (Loyalty Option) for every 15 Shares held on the… Read more
Incannex Healthcare Ltd (IHL. ASX) (Nasdaq: IXHL) announced that it has executed a binding term sheet to wholly acquire APIRx… Read more
Melbourne, Australia, March 21, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical… Read more
Loyalty Option and Piggy-back Options are intended to reward loyal shareholders who have supported Incannex to its current stage of… Read more
Incannex Healthcare Limited lists on the NASDAQ. Mr Joel Latham, Managing Director & CEO of Incannex rings the Closing Bell… Read more
“Considering weakened market conditions on the Nasdaq and more specifically the Nasdaq Biotech Index, which has corrected circa 20% in… Read more
Incannex Healthcare Limited (ASX:IHL), (‘Incannex” or the ‘Company’) a clinical stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and… Read more
Sign up to our mailing list to access our research reports.
By submitting your details, you agree to our Terms of Service.